New York, NYNCT07801664Now EnrollingIRB Ready

Prostate Cancer Clinical Trial in New York, NY

Access cutting-edge prostate cancer treatment through this phase 2 clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by NYU Langone Health

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access prostate cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related prostate cancer treatment provided free

Apply for This New York Location

Check if you qualify for this prostate cancer clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This Prostate Cancer Study in New York

For this study, high risk prostate cancer patients with lower risk ARTERA scores will be treated with 6 months of Androgen Deprivation Therapy (ADT) in conjunction with dose escalated radiotherapy to the prostate and nodes. Specifically, patients enrolled in this study will undergo one of several dose-escalated forms of radiotherapy which would include SBRT with or without a brachytherapy boost.

Sponsor: NYU Langone Health

Who Can Participate

Inclusion Criteria

Ability to understand and willingness to sign a written informed consent document
18 years of age or older male participants
Biopsy proven prostate cancer meeting at least one of the following high-risk criteria: Gleason score 8-10 OR; Baseline PSA \>20 up to and including 40 ng/ml OR; Patients with Gleason score 6-7 remain eligible if the PSA criterion (\>20 ng/mL) is met OR; MRI Radiographic stage T1-T3 disease without evidence of nodal involvement
No imaging evidence of nodal metastases on baseline MRI/ CT of the pelvis and PET-PSMA scans
Low risk or intermediate risk ARTERA AI scores
Serum testosterone ≥ 120 ng/dL determined prior to ADT start
At least 4 weeks must have elapsed from major surgery
Karnofsky Performance Status (KPS) \> 80
Prostate size \< 90 cc
MRI findings: Lesion may have extracapsular extension (ECE)
International Prostate Symptom Score (IPSS) \< 22
Satisfy all MRI screening criteria and be willing to fill out the standard MRI screening form

Exclusion Criteria

Gleason score 6 or 7 in the absence of PSA \>20 ng/mL
PSA \>40 ng/mL
Prior or concurrent androgen deprivation therapy for prostate cancer of \>3 months duration
High Risk ARTERA scores
MRI findings: suspicious nodal metastases
Evidence of regional lymphadenopathy or metastatic disease on MRI/CT or PSMA PET scan
Metallic implant or device in the pelvis that might distort the local magnetic field and compromise quality of mp-MRI
Contra-indications to receiving gadolinium contrast
Pelvic or Prostate MRI or CT (MRI preferred) evidence of radiographic T4, or N1 disease or bone disease
Prior treatment for prostate cancer, including history of chemotherapy or surgery for prostate cancer (except for prior \[transurethral resection of prostate\] TURP or greenlight \[photo selective vaporization of prostate\] PVP which would be allowed)
History of another malignancy within the previous 2 years except for the following: adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, currently in complete remission, or any other cancer that has been in complete remission for at least 3 years. Patients with Crohn's disease or ulcerative colitis
Currently on any ARPis (including but not limited to: enzalutamide, apalutamide, darolutamide, or abiraterone)
Prior pharmacologic androgen deprivation therapy (ADT) for prostate cancer is permitted under the following (2) conditions: 1) Participants meeting this criterion will be assigned to a separate stratum within each primary treatment cohort. 2) Patients remain eligible for enrollment provided they have received no more than 3 months of ADT in total, regardless of whether ADT was initiated before screening or registration.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT07801664) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Prostate Cancer Treatment Options in New York, NY

If you're searching for prostate cancer treatment options in New York, NY, this clinical trial (NCT07801664) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced prostate cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all prostate cancer clinical trials near you to find additional studies recruiting in your area.

More Prostate Cancer Trials in New York, NY

See all prostate cancer clinical trials recruiting in New York — not just this study.

Browse Prostate Cancer Trials in New York →

Browse More Trials by Condition

Prostate Cancer TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY